Symptomatic Tenosynovial Giant Cell Tumor

Drug	Drug Name	Drug Description
DB12978	Pexidartinib	An antitumor agent that is used for the treatment of rare disease tenosynovial giant cell tumors (TGCT) by inhibiting colony-stimulating factor 1 and its receptor.

Drug	Drug Name	Target	Type
DB12978	Pexidartinib	Cytochrome P450 3A4	enzyme
DB12978	Pexidartinib	UDP-glucuronosyltransferase 1-4	enzyme
DB12978	Pexidartinib	Macrophage colony-stimulating factor 1 receptor	target
DB12978	Pexidartinib	Cytochrome P450 2B6	enzyme
DB12978	Pexidartinib	Cytochrome P450 2C9	enzyme
DB12978	Pexidartinib	UDP-glucuronosyltransferase 1-1	enzyme
DB12978	Pexidartinib	Multidrug and toxin extrusion protein 1	transporter
DB12978	Pexidartinib	Multidrug and toxin extrusion protein 2	transporter
DB12978	Pexidartinib	Solute carrier organic anion transporter family member 1B1	transporter
DB12978	Pexidartinib	Solute carrier organic anion transporter family member 1B3	transporter
DB12978	Pexidartinib	Solute carrier organic anion transporter family member 2B1	transporter
DB12978	Pexidartinib	Serum albumin	carrier
DB12978	Pexidartinib	Alpha-1-acid glycoprotein 1	carrier
DB12978	Pexidartinib	Mast/stem cell growth factor receptor Kit	target
DB12978	Pexidartinib	Receptor-type tyrosine-protein kinase FLT3	target
DB12978	Pexidartinib	Platelet-derived growth factor receptor beta	target

Drug	Drug Name	Phase	Status	Count